Assessment of second-line antiretroviral regimens for HIV therapy in Africa.

Míreanna comhchosúla

• Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial
  de réir: Hakim, J, et al.
  Foilsithe / Cruthaithe: (2017)
• Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial
  de réir: Hakim, J, et al.
  Foilsithe / Cruthaithe: (2017)
• Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial
  de réir: Paton, N, et al.
  Foilsithe / Cruthaithe: (2017)
• Evolution of protease inhibitor resistance in HIV-1-infected patients failing protease inhibitor monotherapy as second-line therapy in low-income countries: an observational analysis within the EARNEST randomised trial
  de réir: Thompson, J, et al.
  Foilsithe / Cruthaithe: (2018)
• HIV-1 viral load and resistance in genital secretions in patients taking protease-inhibitor-based second-line therapy in Africa
  de réir: Hoppe, A, et al.
  Foilsithe / Cruthaithe: (2017)